A regional finalist in science and technology
EY Canada announced its 2026 regional finalists on June 3, recognizing more than 130 entrepreneurs across four Canadian regions. On the official Pacific finalists page, Jessica Hu is listed in the Science and Technology category with GBM Health Holding Ltd. The listing gives the company a clear public reference point at a moment when its group structure and longer-term direction are becoming more visible.
The finalist designation is meaningful, but it is also a specific stage in the EY Entrepreneur Of The Year® process. It is not a regional category award, a national award or a technical endorsement of GBM’s products. EY Canada states that regional finalists were selected by independent judging panels using criteria that include entrepreneurial spirit, leadership, purpose, growth and impact.
For Jessica and GBM, the recognition is an opportunity to explain how the business developed. GBM did not begin as a fully formed group with every component designed in advance. Gene Bio Medical first built commercial relationships and practical operating knowledge in diagnostics. Research activities, new technologies and international opportunities were added as the business encountered new needs and potential partners.
Connecting research, commercialization and market access
GBM Health Group is being developed as a growing portfolio of health businesses rather than as a single-product company. Its role is to connect research, commercialization and international market access across diagnostics, health technology and consumer health. The group’s current message—Health Innovation, Connected.—describes that coordinating role without claiming that every capability is already complete.
The approach responds to a practical challenge faced by many smaller health-technology companies. Scientific work, regulatory planning, production, distribution and market development are often treated as separate activities. A promising technology may perform well in a research environment while still lacking a suitable manufacturing pathway, quality plan, regulatory strategy or credible route to customers. GBM’s objective is to help close those gaps around selected opportunities.
The group aims to maintain responsibility for important intellectual property, brands, quality standards and commercial channels while working with researchers, qualified manufacturers, strategic partners and potential joint-venture participants where appropriate. Each project still requires its own technical, regulatory and commercial validation. The model should not be understood as a claim that GBM owns every facility or operates every capability at the same scale.
Artificial intelligence is also becoming part of this work where data analysis can support diagnostic research and decision-making. For GBM, AI is not intended to be a general label added to every project. Its value depends on whether it addresses a defined problem, uses reliable data and fits into a credible scientific, clinical and regulatory pathway.
Why the recognition matters now
For a growing founder-led company, external recognition can make an evolving business easier to understand. Some audiences first encountered GBM through Gene Bio Medical and its operating work. Others know Geno10X through research collaborations, or have met the group through international market-development programs. The EY Pacific finalist listing brings those strands into a single public milestone.
The official page identifies Jessica Hu and GBM Health Holding Ltd. within the Science and Technology category without requiring the company to present itself as larger or more established than it is. That distinction matters. GBM remains a relatively small organization with an ambitious agenda that must be advanced through careful priorities, stronger governance, documented results and the right partners.
Recognition can create conversations, but it does not replace the work required to turn research programs and commercial opportunities into durable businesses. The value of this milestone is therefore not visibility alone. It is the opportunity to describe GBM with greater precision: a health business group built through operating experience and focused on connecting science, products and markets.
The next stage of the program—and the business
EY Canada’s June announcement states that the 2026 program will proceed to further judging. Regional category award recipients and one overall winner for each region are scheduled to be announced in October, followed by the national program in November. Until those later stages are completed, Jessica’s confirmed status is EY Entrepreneur Of The Year® 2026 Pacific finalist in the Science and Technology category.
Within GBM, work continues independently of the award process. Near-term priorities include presenting the group’s structure more clearly, strengthening the connection between research and commercialization, evaluating international opportunities on their practical merits and developing partnerships that add capabilities the company should not attempt to build alone.
The finalist recognition acknowledges the entrepreneurial work completed so far while leaving room for an honest account of what is still being built. For GBM, that is the right balance: recognizing progress without overstating scale, and using greater visibility to support the next stage of responsible growth.